Serum adiponectin and resistin levels in patients with polycystic ovarian syndrome and their clinical implications

Abstract

In this study, serum adiponectin and resistin levels were determined in 46 patients with polycystic ovarian syndrome (PCOS), and their correlation with serum sexual hormones and insulin resistance (IR) were examined. The subjects included 26 obese patients with body mass index (BMI)>25 and 20 non-obese patients with BMI⩽25, with 25 obese and 25 non-obese healthy volunteers without PCOS serving as controls. Serum adiponectin and resistin levels in all subjects were measured, and endocrinal and metabolic indices were also analysed. Our results showed that the serum adiponectin levels in both obese and non-obese PCOS groups were significantly lower than their controls, while the serum resistin levels in obese and non-obese PCOS group were significantly higher than in their controls (P<0.001). The serum adiponectin level was significantly lower and serum resistin level significantly higher in the non-obese PCOS group as compared with the obese control group (P<0.05). Serum adiponectin level was negatively correlated with FIN, HOMA-IR, LH and LH/FSH (P<0.05), but serum resistin level was positively correlated with FIN, HOMA-IR, LH and LH/FSH (P<0.05). We are led to conclude that PCOS patients have obvious IR, low serum adiponectin and high serum resistin, and adiponectin and resistin might play important roles in the pathogenesis of IR in PCOS patients.

Keywords

polycystic ovary syndrome / adiponectin / resistin

References

[1] PfeiferS.M., DayalM.. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am, 2003, 30(2): 337-352

[2] SaltielA.R., KahnC.R.. Insulin signaling and the regulation of glucose and lipid metabolism. Nature, 2001, 414(6865): 799-806

[3] TrayhurnP., BeattieJ.H.. Physiological role of adipose tissue: white adipose tissue as endocrine and secretory organ. Proc Nutr Soc, 2001, 60(3): 329-339

[4] GlueckC.J., MorrisonJ.A., WangP.. Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome. J Pediatr Endocrinol Metab, 2008, 21(10): 973-984

[5] O’MearaN.M., BlackmanJ.D., EhrmannD.A., et al.. Defects in β-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab, 1993, 76(5): 1241-1247

[6] DunaifA., FinegoodD.T.. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab, 1996, 81(3): 942-947

[7] MoralesA.J., LaughlinG.A., ButzowT., et al.. Insulin, somatotropic and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab, 1996, 81(8): 2854-2864

[8] ConwayG.S., ClarkP.M., WongD.. Hyperinsulinemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin. Clin Endocrinol, 1993, 38(2): 219-222

[9] YildizB.O., YaraliH., OguzH., et al.. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2003, 88(5): 2031-2036

[10] KentS.C., GnatukC.L., KunselmanA.R., et al.. Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab, 2008, 93(5): 1662-1669

[11] QuJ., WangY., WuX., et al.. Insulin resistance directly contributes to androgenic potential within ovarian theca cells. Fertil Steril, 2009, 91(5): 1990-1997

[12] BillaE., KapollaN., NicopoulouS.C., et al.. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol, 2009, 25(7): 427-434

[13] RiceS., ChristoforidisN., GaddC., et al.. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod, 2005, 20(2): 373-381

[14] XiangK.S., JiaW.P., LuJ.Q., et al.. The impact of obesity on metabolic syndrome in Chinese aged over 40 in Shanghai, China. Chin J Inter Med (Chinese), 2000, 39(4): 224-228

[15] WeyerG., FunahashiT., TanakaS., et al.. Hypoadipon-ectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001, 86(5): 1930-1935

[16] YangW.S., LeeW.J., FunahashiT., et al.. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocinol Metab, 2001, 86(8): 3815-3819

[17] SteppanC.M., BaileyS.T., BhatS., et al.. The hormone resistin links obesity to diabetes. Nature, 2001, 409(6818): 307-312

[18] KawashimaJ., TsuruzoeK., MotoshimaH., et al.. Insulin down-regulates resistin mRNA through the synthesis of protein(s) that could accelerate the degradation of resistin mRNA in 3T3-L1 adipocytes. Diabetologia, 2003, 46(2): 231-240

[19] BahiaL., AguiarL.G., VillelaN., et al.. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics, 2006, 61(5): 433-40

[20] SeowK.M., JuanC.C., WuL.Y., et al.. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod, 2004, 19(1): 48-53